Q2 2026 Cushing Syndrome and Hypercortisolism Market Developments

Corcept Therapeutics advanced its Cushing syndrome portfolio through new Korlym evidence and the Lifyorli NDA resubmission.

Crinetics expanded its endocrine research with atumelnant data in ACTH-dependent Cushing syndrome.

Recordati Rare Diseases strengthened Isturisa awareness, education, and U.S. market adoption.

Sparrow Pharmaceuticals shared clofutriben findings in patients with elevated cortisol and difficult-to-control type 2 diabetes.